Literature DB >> 25425690

Inhibition of c-Kit by tyrosine kinase inhibitors.

Allison Galanis1, Mark Levis2.   

Abstract

Entities:  

Keywords:  c-Kit inhibition; hair depigmentation; myelosuppression; tyrosine kinase inhibitors

Mesh：

Substances：

Year:  2014        PMID： 25425690      PMCID： PMC4349281          DOI： 10.3324/haematol.2014.117028

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib.

Authors:  Valeria Brazzelli; Vincenzo Grasso; Vincenzo Barbaccia; Giambattista Manna; Nicolò Rivetti; Marco Zecca; Giovanna Giorgiani; Camilla Vassallo; Giovanni Borroni
Journal:  Acta Derm Venereol       Date:  2012-03       Impact factor: 4.437

2.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

3.  Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

Authors:  Jorge E Cortes; Hagop Kantarjian; James M Foran; Darejan Ghirdaladze; Mamia Zodelava; Gautam Borthakur; Guy Gammon; Denise Trone; Robert C Armstrong; Joyce James; Mark Levis
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

4.  FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.

Authors:  Takashi Sato; Xiaochuan Yang; Steven Knapper; Paul White; B Douglas Smith; Steven Galkin; Donald Small; Alan Burnett; Mark Levis
Journal:  Blood       Date:  2011-01-24       Impact factor: 22.113

5.  Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.

Authors:  John P Crown; Véronique Diéras; Elzbieta Staroslawska; Denise A Yardley; Thomas Bachelot; Neville Davidson; Hans Wildiers; Peter A Fasching; Olivier Capitain; Manuel Ramos; Richard Greil; Francesco Cognetti; George Fountzilas; Maria Blasinska-Morawiec; Cornelia Liedtke; Rolf Kreienberg; Wilson H Miller; Vanessa Tassell; Xin Huang; Jolanda Paolini; Kenneth A Kern; Gilles Romieu
Journal:  J Clin Oncol       Date:  2013-07-15       Impact factor: 44.544

6.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

Authors:  Walter Fiedler; Hubert Serve; Hartmut Döhner; Michael Schwittay; Oliver G Ottmann; Anne-Marie O'Farrell; Carlo L Bello; Randy Allred; William C Manning; Julie M Cherrington; Sharianne G Louie; Weiru Hong; Nicoletta M Brega; Giorgio Massimini; Paul Scigalla; Wolfgang E Berdel; Dieter K Hossfeld
Journal:  Blood       Date:  2004-09-30       Impact factor: 22.113

7.  Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.

Authors:  Katherine G Moss; Guy C Toner; Julie M Cherrington; Dirk B Mendel; A Douglas Laird
Journal:  J Pharmacol Exp Ther       Date:  2003-09-09       Impact factor: 4.030

8.  Phase I trial of pazopanib in patients with advanced cancer.

Authors:  Herbert I Hurwitz; Afshin Dowlati; Shermini Saini; Shawna Savage; A Benjamin Suttle; Diana M Gibson; Jeffrey P Hodge; Elmar M Merkle; Lini Pandite
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

9.  Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.

Authors:  Allison Galanis; Hayley Ma; Trivikram Rajkhowa; Abhijit Ramachandran; Donald Small; Jorge Cortes; Mark Levis
Journal:  Blood       Date:  2013-11-13       Impact factor: 22.113

10.  A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.

Authors:  Ruth Plummer; Ayman Madi; Melinda Jeffels; Heike Richly; Bahar Nokay; Stephen Rubin; Howard A Ball; Steve Weller; Jeffrey Botbyl; Diana M Gibson; Max E Scheulen
Journal:  Cancer Chemother Pharmacol       Date:  2012-10-11       Impact factor: 3.333
View more
  40 in total

1.  Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Authors:  Jorge Cortes; Alexander E Perl; Hartmut Döhner; Hagop Kantarjian; Giovanni Martinelli; Tibor Kovacsovics; Philippe Rousselot; Björn Steffen; Hervé Dombret; Elihu Estey; Stephen Strickland; Jessica K Altman; Claudia D Baldus; Alan Burnett; Alwin Krämer; Nigel Russell; Neil P Shah; Catherine C Smith; Eunice S Wang; Norbert Ifrah; Guy Gammon; Denise Trone; Deborah Lazzaretto; Mark Levis
Journal:  Lancet Oncol       Date:  2018-05-31       Impact factor: 41.316

2.  Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI.

Authors:  Naranie Shanmuganathan; Susan Branford; Timothy P Hughes; Devendra Hiwase
Journal:  Blood Adv       Date:  2019-02-12

3.  Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia.

Authors:  Christine M McMahon; Jonathan Canaani; Bryan Rea; Rachel L Sargent; Julianne N Qualtieri; Christopher D Watt; Jennifer J D Morrissette; Martin Carroll; Alexander E Perl
Journal:  Blood Adv       Date:  2019-05-28

4.  Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.

Authors:  Lauren Y Lee; Daniela Hernandez; Trivikram Rajkhowa; Samuel C Smith; Jayant Ranganathan Raman; Bao Nguyen; Donald Small; Mark Levis
Journal:  Blood       Date:  2016-12-01       Impact factor: 22.113

Review 5.  Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia.

Authors:  Longzhen Cui; Yan Liu; Yifan Pang; Tingting Qian; Liang Quan; Zhiheng Cheng; Yifeng Dai; Xu Ye; Ying Pang; Jinlong Shi; Xiaoyan Ke; Depei Wu; Lin Fu
Journal:  Cancer Gene Ther       Date:  2019-07-11       Impact factor: 5.987

6.  Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study.

Authors:  Kensuke Usuki; Hiroshi Handa; Ilseung Choi; Takahiro Yamauchi; Hiroatsu Iida; Tomoko Hata; Shoichi Ohwada; Noriko Okudaira; Kota Nakamura; Sakura Sakajiri
Journal:  Int J Hematol       Date:  2019-07-29       Impact factor: 2.490

7.  Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Authors:  Jorge E Cortes; Martin S Tallman; Gary J Schiller; Denise Trone; Guy Gammon; Stuart L Goldberg; Alexander E Perl; Jean-Pierre Marie; Giovanni Martinelli; Hagop M Kantarjian; Mark J Levis
Journal:  Blood       Date:  2018-06-06       Impact factor: 22.113

8.  Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.

Authors:  Ellen Weisberg; Chengcheng Meng; Abigail E Case; Martin Sattler; Hong L Tiv; Prafulla C Gokhale; Sara J Buhrlage; Xiaoxi Liu; Jing Yang; Jinhua Wang; Nathanael Gray; Richard M Stone; Sophia Adamia; Patrice Dubreuil; Sebastien Letard; James D Griffin
Journal:  Br J Haematol       Date:  2019-07-15       Impact factor: 6.998

Review 9.  Gilteritinib: potent targeting of FLT3 mutations in AML.

Authors:  Mark Levis; Alexander E Perl
Journal:  Blood Adv       Date:  2020-03-24

10.  A Novel System for Functional Determination of Variants of Uncertain Significance using Deep Convolutional Neural Networks.

Authors:  Lior Zimmerman; Ori Zelichov; Arie Aizenmann; Zohar Barbash; Michael Vidne; Gabi Tarcic
Journal:  Sci Rep       Date:  2020-03-06       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.